CardiolRx Phase II Results Support Heart Disease Therapy
TORONTO, ON, May 7, 2026 Cardiol Therapeutics Inc. announced that results from its Phase II MAvERIC study evaluating CardiolRx™...
Biotechnology
Advertisement
Edgewise Advances Muscle and Heart Disease Pipeline
BOULDER, Colo., May 7, 2026 Edgewise Therapeutics reported first quarter 2026 financial results while highlighting major progress across its...
Armata Gains FDA Fast Track for AP-SA02 Therapy
LOS ANGELES, May 7, 2026 Armata Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has granted Fast...
BioMarin VOXZOGO Shows Long-Term Growth Benefits
San Rafael, California, United States | May 2, 2026 BioMarin Pharmaceutical Inc. has presented new long-term clinical data for...
Scribe Therapeutics Showcases CRISPR and STX-1150 Data
Alameda, California, United States | April 30, 2026 Scribe Therapeutics has announced significant advancements in its engineered CRISPR gene...
Advertisements
Profluent, Lilly Partner to Advance AI Gene Editing Tech
EMERYVILLE, CALIFORNIA, April 29, 2026 Profluent has announced a strategic multi-program research collaboration with Eli Lilly and Company to...
Intellia Nears Phase 3 CRISPR Data in HAE Breakthrough
Cambridge, Massachusetts | April 24, 2026 Intellia Therapeutics has announced a pivotal milestone in genetic medicine, confirming that it...
Telomir Acquires TELI to Secure Global Telomir-1 Rights
MIAMI, FL, April 24, 2026 Telomir Pharmaceuticals has announced the successful completion of its acquisition of TELI Pharmaceuticals, securing...
Regeneron Otarmeni Gene Therapy FDA Hearing Breakthrough
TARRYTOWN, N.Y., April 23, 2026 Regeneron Pharmaceuticals has achieved a landmark milestone as the U.S. Food and Drug Administration...
Eli Lilly to Acquire Kelonia for In Vivo CAR-T Breakthrough
INDIANAPOLIS and BOSTON, Mass., April 20, 2026 Eli Lilly and Company has announced a landmark agreement to acquire Kelonia...
Advertisement
